NFKB1 and colorectal adenocarcinoma: Studies have shown that LYCO suppresses the activation of NF-kB prompted by various inflammatory mediators and exerts genoprotective effects against oxidative and methylation damage in HT-29 colorectal adenocarcinoma cells [25].